| Exclusion Criteria: | 1) Received cytotoxic chemotherapy or radiotherapy within 21 days (or 42 days for nitrosoureas or mitomycin C) prior to entering the study, or have not recovered (> Grade 1 by CTCAE v. 3) from adverse events (except alopecia) due to agents administered more than 28 days earlier
2) Received an investigational agent within 14 days of starting AP24534
3) Malabsorption syndrome or other illness that could affect oral absorption
4) Significant uncontrolled cardiac disease
5) Patients taking medicinal products that are known to be associated with prolongation of the QT interval on the electrocardiogram
6) Uncontrolled hypertension (Diastolic BP > 100 mm Hg; Systolic > 150 mm Hg)
7) Uncontrolled intercurrent illness including, but not limited to the following: ongoing or active infection, uncontrolled seizure disorder, psychiatric or social circumstances that would limit compliance with study requirements
8) Pregnant. Pregnant women are excluded from this study because the teratogenic or abortifacient effects of AP24534 are not known at this time. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AP24534, breastfeeding should be discontinued if the mother is treated with AP24534
9) Known infection with HIV
10) Autologous or allogeneic stem cell transplant < 3 months (90 days) prior to enrollment; any evidence of on-going graft versus host disease (GVHD), or GVHD requiring immunosuppressive therapy
11) Another primary malignancy within the past 3 years (except for non-melanoma skin cancer or cervical cancer in situ)
12) Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise patient safety or interfere with the evaluation of the safety of the drug
13) Major surgery (with the exception of intravenous catheter placement or bone marrow biopsy) within 14 days prior to initiating AP24534 therapy. |